This is a routine shelf replacement with no immediate capital raise. Monitor for future prospectus supplements that would signal an actual offering. The I.B.6 limitation restricts primary offerings to ~$17.5M in any 12-month period unless public float exceeds $75M, capping near-term dilution from primary offerings.
Drugs in focus
SCYX drug pipeline →SCY-770
● Neutral Named in this S-3- Impact
- Phase
- Phase 1 completed; Phase 2 ready
- Time to market
- Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
- Next catalyst
- None dated
What to watchWatch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $3.30entry
- T+1 · 11d ago +6.06%α +5.75% · $3.50
- T+5 · 5d ago +0.91%α −2.38% · $3.33
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
SCYNEXIS filed a new S-3 shelf registration to replace its expiring 2023 S-3, carrying forward the full $200 million of unsold securities. No new securities or additional registration fees are involved. The filing is a routine administrative replacement that maintains the company's ability to raise capital through common stock, preferred stock, debt securities, or warrants over the next three years.
Key Financial Metrics
Key Facts
- Filed S-3 to replace expiring S-3 (File No. 333-275520) due to expire November 27, 2026
- Carrying forward $200,000,000 in unsold securities from the prior shelf; no new securities registered
- No additional registration fee due; $29,520 in previously paid fees carried forward
- Public float approximately $52.5 million as of November 3, 2026
- Subject to General Instruction I.B.6 limiting primary offerings to one-third of public float ($17.5M) in any 12-month period unless public float exceeds $75M
- Company is a clinical-stage biotech with lead programs SCY-770 (ADPKD) and SCY-247 (antifungal); only approved product BREXAFEMME licensed to GSK
- 10-Q filed same day shows ongoing operating losses and need for capital to fund development
Financial Impact
Shelf capacity of $200 million maintained; no immediate capital raise
Risk Factors
- Future offerings under this shelf could cause dilution to existing shareholders
- Company has a history of frequent capital raises (4 offering/registration filings in last 24 months)
- Clinical-stage biotech with no recurring product revenue and ongoing cash burn requires continued financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-448707 |
| Document: d167987dexfilingfees.htm | 0001193125-26-448707 |
| Document: d167987dex51.htm | 0001193125-26-448707 |
| Document: d167987dex231.htm | 0001193125-26-448707 |
| Document: 0001193125-26-448707-index-headers.html | 0001193125-26-448707 |
| Document: 0001193125-26-448707-index.html | 0001193125-26-448707 |
| Document: 0001193125-26-448707.txt | 0001193125-26-448707 |
Track record
14 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Viewing Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers